Literature DB >> 23250949

Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis.

Tiago Rafael Veloso1, Aziz Chaouch, Thierry Roger, Marlyse Giddey, Jacques Vouillamoz, Paul Majcherczyk, Yok-Ai Que, Valentin Rousson, Philippe Moreillon, José Manuel Entenza.   

Abstract

Animal models of infective endocarditis (IE) induced by high-grade bacteremia revealed the pathogenic roles of Staphylococcus aureus surface adhesins and platelet aggregation in the infection process. In humans, however, S. aureus IE possibly occurs through repeated bouts of low-grade bacteremia from a colonized site or intravenous device. Here we used a rat model of IE induced by continuous low-grade bacteremia to explore further the contributions of S. aureus virulence factors to the initiation of IE. Rats with aortic vegetations were inoculated by continuous intravenous infusion (0.0017 ml/min over 10 h) with 10(6) CFU of Lactococcus lactis pIL253 or a recombinant L. lactis strain expressing an individual S. aureus surface protein (ClfA, FnbpA, BCD, or SdrE) conferring a particular adhesive or platelet aggregation property. Vegetation infection was assessed 24 h later. Plasma was collected at 0, 2, and 6 h postinoculation to quantify the expression of tumor necrosis factor (TNF), interleukin 1α (IL-1α), IL-1β, IL-6, and IL-10. The percentage of vegetation infection relative to that with strain pIL253 (11%) increased when binding to fibrinogen was conferred on L. lactis (ClfA strain) (52%; P = 0.007) and increased further with adhesion to fibronectin (FnbpA strain) (75%; P < 0.001). Expression of fibronectin binding alone was not sufficient to induce IE (BCD strain) (10% of infection). Platelet aggregation increased the risk of vegetation infection (SdrE strain) (30%). Conferring adhesion to fibrinogen and fibronectin favored IL-1β and IL-6 production. Our results, with a model of IE induced by low-grade bacteremia, resembling human disease, extend the essential role of fibrinogen binding in the initiation of S. aureus IE. Triggering of platelet aggregation or an inflammatory response may contribute to or promote the development of IE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250949      PMCID: PMC3584864          DOI: 10.1128/IAI.01030-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

Review 1.  Surface protein adhesins of Staphylococcus aureus.

Authors:  T J Foster; M Höök
Journal:  Trends Microbiol       Date:  1998-12       Impact factor: 17.079

2.  Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo.

Authors:  John H Vernachio; Arnold S Bayer; Brenda Ames; Dawn Bryant; Bradley D Prater; Peter J Syribeys; Elena L Gorovits; Joseph M Patti
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A.

Authors:  Anthony Loughman; J Ross Fitzgerald; Marian P Brennan; Judy Higgins; Robert Downer; Dermot Cox; Timothy J Foster
Journal:  Mol Microbiol       Date:  2005-08       Impact factor: 3.501

4.  New concepts in the pathophysiology of infective endocarditis.

Authors:  Eleonora Widmer; Yok-Ai Que; José M Entenza; Philippe Moreillon
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

5.  Three new members of the serine-aspartate repeat protein multigene family of Staphylococcus aureus.

Authors:  Elisabet Josefsson; Kirk W McCrea; Deirdre Ni Eidhin; David O'Connell; Jos Cox; Magnus Hook; Timothy J Foster
Journal:  Microbiology (Reading)       Date:  1998-12       Impact factor: 2.777

6.  Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

Authors:  U Fluckiger; P Moreillon; J Blaser; M Bickle; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  Natural variability of in vitro adherence to fibrinogen and fibronectin does not correlate with in vivo infectivity of Staphylococcus aureus.

Authors:  Mathilde Ythier; Jose M Entenza; Jacques Bille; François Vandenesch; Michèle Bes; Philippe Moreillon; Olga Sakwinska
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

8.  Characterization of Staphylococcus aureus-platelet binding by quantitative flow cytometric analysis.

Authors:  M R Yeaman; P M Sullam; P F Dazin; D C Norman; A S Bayer
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

9.  Usefulness of cytokines interleukin-6 and interleukin-2R concentrations in diagnosing active infective endocarditis involving native valves.

Authors:  Peter Alter; Jutta Hoeschen; Michael Ritter; Bernhard Maisch
Journal:  Am J Cardiol       Date:  2002-06-15       Impact factor: 2.778

10.  Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis.

Authors:  Yok-Ai Que; Jacques-Antoine Haefliger; Lionel Piroth; Patrice François; Eleonora Widmer; José M Entenza; Bhanu Sinha; Mathias Herrmann; Patrick Francioli; Pierre Vaudaux; Philippe Moreillon
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307

View more
  18 in total

1.  Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus.

Authors:  Tiago Rafael Veloso; Frank Oechslin; Yok-Ai Que; Philippe Moreillon; José Manuel Entenza; Stefano Mancini
Journal:  Pathog Dis       Date:  2015-08-26       Impact factor: 3.166

Review 2.  New Threats from an Old Foe: Methicillin-Resistant Staphylococcus aureus Infections in Neonates.

Authors:  Ying Dong; Kirsten Glaser; Christian P Speer
Journal:  Neonatology       Date:  2018-05-25       Impact factor: 4.035

Review 3.  Infective endocarditis.

Authors:  Thomas L Holland; Larry M Baddour; Arnold S Bayer; Bruno Hoen; Jose M Miro; Vance G Fowler
Journal:  Nat Rev Dis Primers       Date:  2016-09-01       Impact factor: 52.329

Review 4.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall.

Authors:  J Claes; L Liesenborghs; M Peetermans; T R Veloso; D Missiakas; O Schneewind; S Mancini; J M Entenza; M F Hoylaerts; R Heying; P Verhamme; T Vanassche
Journal:  J Thromb Haemost       Date:  2017-03-23       Impact factor: 5.824

6.  Pathophysiology of infective endocarditis.

Authors:  Yoav Keynan; Ethan Rubinstein
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

7.  Low efficacy of tobramycin in experimental Staphylococcus aureus endocarditis.

Authors:  C J Lerche; L J Christophersen; H Trøstrup; K Thomsen; P Ø Jensen; H P Hougen; H Bundgaard; N Høiby; C Moser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-06       Impact factor: 3.267

Review 8.  The New Challenge for Heart Endocarditis: From Conventional Prosthesis to New Devices and Platforms for the Treatment of Structural Heart Disease.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh
Journal:  Biomed Res Int       Date:  2021-06-14       Impact factor: 3.411

9.  Role of the serine-rich surface glycoprotein Srr1 of Streptococcus agalactiae in the pathogenesis of infective endocarditis.

Authors:  Ho Seong Seo; Yan Q Xiong; Paul M Sullam
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

10.  Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José M Entenza; Camille Kolenda; Frédéric Laurent; Grégory Resch
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.